

**AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs**

**Decision Making Support Tool**

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0048
Drug name and formulations:		Anoro® Ellipta® 55/22 mcg
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	No issues
Clinical effectiveness	<i>Established licensed product</i>	Equivalent to established products.
Strength of evidence		Moderate
Cost effectiveness or resource impact	<i>£</i>	Cost neutral, same as all other LAMA/LABA combinations.
Place of therapy relative to available treatments	<i>1/2<sup>nd</sup> tier</i>	In line with other LAMA/LABA options, treatment pathway outlined in COPD guidelines.
National guidance and priorities	<i>NICE, MTRAC</i>	Consistent with the Global Initiative for Obstructive Lung Disease (GOLD) guidelines updated in 2017, and the NICE COPD Clinical Guideline, although this has not been updated recently and does not include the LAMA/LABA combinations.
Local health priorities	<i>CCG views</i>	CCGs supportive.
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	N/A

**Decision Summary**

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	Green
Implementation requirements:	
Implementation monitoring:	